focus -WSS

focus

author：hotspot 2025-09-30 17:59:42 - browse：85

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Bispecific antibodies are next new thing in cancer immunotherapy

WSS

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

Sickle cell gene therapy cures need to be accessible in Africa

Senate panel passes drug pricing bills, but drops one PBM reform

Patients, doctors are clashing about side effects of hormonal birth control

Can medical device makers keep up in the race to treat obesity?

Can medical device makers keep up in the race to treat obesity?

Wikipedia

focus

leisure time

As demand for Covid shots wanes, Moderna seeks its next success

The debate over Covid

Sports medicine is finally prioritizing gender equality

Women's World Cup brings attention to abuse in soccer

DIEP, the 'gold standard' of breast reconstruction, is under threat

How are insurers handling Leqembi and related scans?

Tori Bowie and the unacceptable rates of Black maternal death

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

Malaria cases in Florida and Texas: Here’s what you need to know

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

leisure time

Grail's uphill battle for Medicare to cover its cancer screening test

Novo: Oral version of Ozempic leads to 15% weight loss

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

Digital health funding stays low as a new reality sets in

Altering the blood type of lungs raises potential for universal organs for transplants

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

focus

hotspot

entertainment

hotspot